Centre of Vaccinology, CMU, 1 rue Michel-Servet, 1211 Geneva 4, Switzerland University of Geneva, Switzerland.
Clin Chest Med. 2009 Dec;30(4):811-26, x. doi: 10.1016/j.ccm.2009.08.014.
The only currently licensed tuberculosis (TB) vaccine, bacille Calmette Guérin, confers incomplete protection against tuberculosis, and is not safe in infants infected with the human immunodeficiency virus. A new, safe vaccine regimen, which better protects against lung disease, is urgently needed to control TB in high-burden countries. Multiple candidate vaccines have shown promise in preclinical studies, and are now entering phase 1 to 2B clinical trials. This article discusses progress in the field and issues surrounding safety, reactogenicity, immunogenicity, and efficacy testing of new TB vaccines.
目前唯一获得许可的结核病（TB）疫苗卡介苗对结核病的保护作用不完全，并且对感染人类免疫缺陷病毒的婴儿不安全。需要一种新的、安全的疫苗方案，以更好地预防肺部疾病，从而在高负担国家控制结核病。多种候选疫苗在临床前研究中显示出了希望，目前正在进入 1 期至 2B 期临床试验。本文讨论了该领域的进展以及新的结核病疫苗的安全性、反应原性、免疫原性和疗效测试方面的问题。
